All News

2018

December

Media Release / Dec 04, 2018

Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data

Read More
Media Release / Dec 03, 2018

Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1

Read More
Media Release / Dec 02, 2018

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies

Read More
Media Release / Dec 01, 2018

Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers

Read More
Media Release / Dec 01, 2018

Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program

Read More

November

Media Release / Nov 29, 2018

Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe

Read More
Panel discussion at the fourth Novartis Social Business stakeholder dialogue
Featured News / Nov 28, 2018

Discussing innovative solutions to address unmet healthcare needs in Asia

More than 100 people from 15 Asian countries participated in the fourth Novartis Social Business stakeholder dialogue in Singapore on November 20.

Read More
Media Release / Nov 27, 2018

Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)

Read More
Media Release / Nov 27, 2018

Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London

Read More
Story / Nov 26, 2018

An up-close look at cryo-electron microscopy

Scientists are using the imaging technique to see complex molecular structures in stunning detail.

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More